Comparison of NAFLD, MAFLD, MASLD and pure-MASLD characteristics and mortality outcomes in United States adults

Author:

Song Rui,Li Zhao,Zhang Yingzhi,Tan Jiahe,Chen Zhiwei

Abstract

AbstractBackgroundAfter metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD) has recently been redefined again as metabolic dysfunction-associated steatotic liver disease (MASLD). However, the distinctions in characteristics and mortality outcomes between NAFLD, MAFLD, MASLD, and pure-MASLD are still unclear.MethodsWe analyzed data from 6,708 participants in the third National Health and Nutrition Examination Surveys 1988-1994 of United States (US) and their linked mortality through 2019. NAFLD, MAFLD, MASLD and pure MASLD were defined based on respective criteria. Survey-weight adjusted multivariable Cox proportional model was used to study the mortality of the four terms.ResultsThe overall prevalence of NAFLD, MAFLD, MASLD and pure-MASLD was 28.9% (n=1,937), 26.1% (n=1,753), 29.0% (n=1,948), and 26.0% (n=1,741), respectively. For NAFLD, 81.3%, 89.9% and 89.9% fulfilled the criteria for MAFLD, MASLD and pure MASLD. For MAFLD, all were classified into the MASLD, and 89.8% were met the criteria of pure-MASLD. During a median follow-up of 27 years, both individuals with MAFLD and MASLD had higher risk of all-cause mortality (adjusted hazard ratio [aHR]: 1.21, 95% CI 1.09-1.352; and 1.11, 1.00-1.23, respectively). NAFLD and pure-MASLD were not associated with all-cause mortality. All the four terms were associated with increased all-cause mortality in individuals with advanced fibrosis (aHR: 1.66-1.83). Subgroup analyses showed that higher risk of all-cause mortality of NAFLD, MAFLD, MASLD and pure-MASLD were observed in female, age 41-55 years, non-Hispanic white, and never smoking subgroups when focused on moderate-severe hepatic steatosis.ConclusionsIn this US population-based study, MASLD could identify more individuals with all-cause mortality risk than MAFLD, meanwhile, NAFLD and pure-MASLD had similar characteristics and mortality outcomes.

Publisher

Cold Spring Harbor Laboratory

Reference27 articles.

1. Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations;J Clin Transl Hepatol,2020

2. A multi-society Delphi consensus statement on new fatty liver disease nomenclature;J Hepatol,2023

3. NAFLD to MASLD is wokeism?;J Hepatol,2023

4. Emanuele E , Minoretti P . Letter to the Editor: NAFLD, MAFLD or MASLD? cut the Gordian knot with “Ludwig disease”. Hepatology 2023.

5. Can we use old NAFLD data under the new MASLD definition?;J Hepatol,2023

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. The Global Epidemic of Metabolic Fatty Liver Disease;Current Cardiology Reports;2024-02-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3